Our top pick for
Avid Bioservices, Inc is a biotechnology business based in the US. Avid Bioservices shares (CDMO) are listed on the NASDAQ and all prices are listed in US Dollars. Avid Bioservices employs 222 staff and has a trailing 12-month revenue of around USD$69.8 million.
Since the stock market crash in March caused by coronavirus, Avid Bioservices's share price has had significant positive movement.
Its last market close was USD$8.04, which is 10.70% up on its pre-crash value of USD$7.18 and 166.23% up on the lowest point reached during the March crash when the shares fell as low as USD$3.02.
If you had bought USD$1,000 worth of Avid Bioservices shares at the start of February 2020, those shares would have been worth USD$566.35 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,240.73.
|Latest market close||USD$8.04|
|52-week range||USD$3.02 - USD$9.1|
|50-day moving average||USD$7.69|
|200-day moving average||USD$6.7346|
|Wall St. target price||USD$11|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.18|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-19)||-9.66%|
|1 month (2020-10-26)||6.35%|
|3 months (2020-08-26)||-3.02%|
|6 months (2020-05-26)||52.56%|
|1 year (2019-11-26)||50.00%|
|2 years (2018-11-26)||53.44%|
|3 years (2017-11-24)||78.67%|
|5 years (2015-11-25)||538.10%|
Valuing Avid Bioservices stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Avid Bioservices's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Avid Bioservices's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$702,000.
The EBITDA is a measure of a Avid Bioservices's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$69.8 million|
|Gross profit TTM||USD$3.9 million|
|Return on assets TTM||-1.5%|
|Return on equity TTM||-5.35%|
|Market capitalisation||USD$452.8 million|
TTM: trailing 12 months
There are currently 1.9 million Avid Bioservices shares held short by investors – that's known as Avid Bioservices's "short interest". This figure is 24.2% down from 2.6 million last month.
There are a few different ways that this level of interest in shorting Avid Bioservices shares can be evaluated.
Avid Bioservices's "short interest ratio" (SIR) is the quantity of Avid Bioservices shares currently shorted divided by the average quantity of Avid Bioservices shares traded daily (recently around 478157.5308642). Avid Bioservices's SIR currently stands at 4.05. In other words for every 100,000 Avid Bioservices shares traded daily on the market, roughly 4050 shares are currently held short.
However Avid Bioservices's short interest can also be evaluated against the total number of Avid Bioservices shares, or, against the total number of tradable Avid Bioservices shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Avid Bioservices's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Avid Bioservices shares in existence, roughly 30 shares are currently held short) or 0.0344% of the tradable shares (for every 100,000 tradable Avid Bioservices shares, roughly 34 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Avid Bioservices.
Find out more about how you can short Avid Bioservices stock.
We're not expecting Avid Bioservices to pay a dividend over the next 12 months.
Avid Bioservices's shares were split on a 1:7 basis on 10 July 2017. So if you had owned 7 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Avid Bioservices shares – just the quantity. However, indirectly, the new 600% higher share price could have impacted the market appetite for Avid Bioservices shares which in turn could have impacted Avid Bioservices's share price.
Over the last 12 months, Avid Bioservices's shares have ranged in value from as little as $3.02 up to $9.1. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Avid Bioservices's is 2.262. This would suggest that Avid Bioservices's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. It produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, purification, bulk packaging, release and stability testing, and regulatory submission and support. The company also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. It serves biotechnology and pharmaceutical companies. Avid Bioservices, Inc. has a process development and manufacturing agreement with Oragenics, Inc. to develop coronavirus vaccine. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was founded in 1981 and is headquartered in Tustin, California.
Everything we know about the Qilian International Holding Group IPO, plus information on how to buy in.
Everything we know about the AbCellera Biologics IPO, plus information on how to buy in.
Steps to owning and managing CALM, with 24-hour and historical pricing before you buy.
Steps to owning and managing CRR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BG, with 24-hour and historical pricing before you buy.
Steps to owning and managing BCLI, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLBD, with 24-hour and historical pricing before you buy.
Steps to owning and managing BDTX, with 24-hour and historical pricing before you buy.
Steps to owning and managing RILYO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASPN, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.